For CYP24A1 polymorphisms, we found that rs6068816 was significant related to reduction of NSCLC risk (TT vs. CC, OR = 0.31, 95% CI 0.21–0.47; p < 0.001). This evidence concerns the gene CYP24A1 and non-small cell lung carcinoma.